[ad_1]
One of Bristol-Myers Squibb Co.'s major shareholders opposes the company's $ 74 billion deal on the purchase of competitor Celgene Corp., becoming the latest investor to express its dissatisfaction with this transaction.
Wellington Management Co., an investment company holding a stake of about 8% in Bristol-Myers, said on Wednesday that the agreement required shareholders to take too many risks and offered Bristol shares. cheaper to Celgene shareholders. The company also said that the execution of a successful transaction could be more difficult than expected by management ….
[ad_2]
Source link